CN115105546A - Application of Jingfang preparation in improving or treating stomach cold syndrome - Google Patents
Application of Jingfang preparation in improving or treating stomach cold syndrome Download PDFInfo
- Publication number
- CN115105546A CN115105546A CN202210248173.XA CN202210248173A CN115105546A CN 115105546 A CN115105546 A CN 115105546A CN 202210248173 A CN202210248173 A CN 202210248173A CN 115105546 A CN115105546 A CN 115105546A
- Authority
- CN
- China
- Prior art keywords
- jingfang
- parts
- preparation
- stomach
- cold
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/538—Schizonepeta
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/076—Poria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/232—Angelica
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/233—Bupleurum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/236—Ligusticum (licorice-root)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/237—Notopterygium
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/238—Saposhnikovia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/34—Campanulaceae (Bellflower family)
- A61K36/346—Platycodon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/752—Citrus, e.g. lime, orange or lemon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Mycology (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Nutrition Science (AREA)
- Hospice & Palliative Care (AREA)
- Otolaryngology (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention belongs to the technical field of traditional Chinese medicines, and particularly relates to a new application of a Jingfang preparation. The Jingfang preparation is mainly prepared from herba schizonepetae, radix sileris, notopterygium root, radix angelicae pubescentis, radix bupleuri, radix peucedani, rhizoma ligustici wallichii, fructus aurantii, poria cocos, platycodon grandiflorum and liquorice. The Jingfang preparation can obviously reduce the damage of the gastric mucosa caused by the stomach cold and improve the dyspepsia symptom caused by the stomach cold.
Description
Technical Field
The invention relates to a new application of Jingfang granules, in particular to a new application of a Jingfang preparation in preparing a medicine for improving or treating a stomach cold syndrome, and belongs to the technical field of traditional Chinese medicines.
Background
Stomach cold refers to the condition of cold in the stomach caused by overeating raw or cold food and irregular diet. It is mainly manifested as stomach ache, pale taste without thirst, vomiting, etc. Stomach cold is classified as cold pathogen attacking the stomach and stomach qi deficiency cold. The cold attacking the stomach is an excess syndrome, which is usually caused by acute attack and has a short course of disease; however, the deficiency-cold of the stomach-qi is a deficiency syndrome, which usually has a long course of disease, lingering and unhealed, and mild symptoms accompanied by certain deficiency symptoms such as long-term aversion to cold, preference for warmth, pale complexion, etc.
The basic causes of stomach cold are:
1. overeating raw and cold food, and eating too much raw and cold food or taking cold and cold medicine for a long time, so that gastric mucosa is stimulated by cold; 2. irregular diet, often no meal on time, alternate eating with cold and hot food, hunger and hunger, and stomach cold caused by long-term eating; 3. cold environment, suddenly exposed to very cold environment, and due to very cold outside, cold directly enters human body and injures human viscera; 4. mental stimulation, which is rapid in life rhythm, causes long-term mental stress and great stress, thereby promoting aggravation of stomach cold symptoms.
Typical symptoms of stomach cold are mainly:
1. stomach pain, epigastric pain, mild and lingering pain if slight, spasm and pain if severe, especially when cold, can be relieved by warmth. The stomach ache symptom of some patients can be relieved after eating; 2. the patient usually feels light in mouth and cannot taste the food and flavor and always feels thirsty; 3. vomiting, vomiting of clear water or of undigested food; 4. others are accompanied by lassitude, cold body, cold limbs, preference for warmth, gastric cavity with louder water, pale tongue with white coating, wiry and tense pulse or weak pulse.
Disclosure of Invention
The inventor explains that the novel application of the Jingfang preparation is derived from feedback of company staff, and part of company staff find that stomachache caused by stomach cold is obviously reduced or the attack frequency is obviously reduced during taking Jingfang granules for preventing cold. Based on the above use feedback, the applicant has conducted further studies on the use of the Jingfang preparation in the treatment of gastropyretic conditions.
One of the purposes of the invention is to provide the application of the Jingfang preparation in preparing the medicine for improving and/or treating the stomach cold syndrome.
The invention also aims to provide the application of the Jingfang preparation in preparing medicines for improving stomachache, dyspepsia or emesis caused by stomach cold.
The invention also aims to provide the application of the Jingfang preparation in preparing medicines for treating or assisting in treating stomach diseases caused by stomach cold.
Preferably, the stomach diseases include, but are not limited to, gastric ulcer, duodenal ulcer, chronic gastritis, gastroptosis, gastroneurosis, and prolapse of gastric mucosa.
The Jingfang preparation is mainly prepared from the following raw materials:
preferably, the Jingfang preparation can be a clinically acceptable oral preparation.
Further preferably, the clinically acceptable oral preparation includes but is not limited to granules, oral liquid, mixture, syrup, tablets, capsules.
More preferably, the oral preparation is granules and/or mixture. (ii) a
Compared with the prior art, the invention has the remarkable technical effects that:
1. the Jingfang preparation can obviously improve gastric mucosa injury caused by the stomach cold syndrome, reduce the content of inflammatory factors in serum of a model rat and effectively treat the stomach cold syndrome.
2. The Jingfang preparation can obviously improve the symptoms of a stomach cold type dyspepsia mouse, obviously increases the body mass of the mouse, obviously improves the small intestine propulsion rate, obviously increases the gastrogrowth hormone level and obviously reduces the motilin level.
DETAILED DESCRIPTION OF EMBODIMENT (S) OF INVENTION
The present invention is further illustrated by the following examples, which are intended to be purely exemplary and are not intended to limit the scope of the invention, as various equivalent modifications of the invention will occur to those skilled in the art upon reading the present disclosure and fall within the scope of the appended claims.
Example 1 preparation of Jingfang granules
Prescription:
75g of schizonepeta, 75g of divaricate saposhnikovia root, 75g of incised notopterygium rhizome, 75g of doubleteeth pubescent angelica root, 75g of Chinese thorowax root, 75g of whiteflower hogfennel root, 75g of szechuan lovage rhizome, 75g of bitter orange, 75g of Indian buead, 75g of platycodon root and 25g of liquoric root;
the preparation method comprises the following steps:
extracting volatile oil from herba Schizonepetae, radix Saposhnikoviae, Notopterygii rhizoma, radix Angelicae Pubescentis, radix Peucedani, rhizoma Ligustici Chuanxiong, and fructus Aurantii respectively, and preparing into 25% ethanol solution; mixing the residues of rhizoma Ligustici Chuanxiong and fructus Aurantii with Poria, percolating with the above 25% ethanol solution, and collecting percolate; decocting the residues of herba Schizonepetae, radix Saposhnikoviae, Notopterygii rhizoma, radix Angelicae Pubescentis, and radix Peucedani with bupleuri radix, radix Platycodi, and Glycyrrhrizae radix in water twice for 1.5 hr each time, mixing decoctions, filtering, and concentrating the filtrate to obtain soft extract; mixing the percolate and the thick paste, uniformly mixing, standing, filtering, concentrating the filtrate into clear paste with the relative density of 1.30 (80-85 ℃), taking 1 part of the clear paste, adding 6 parts of sucrose powder, uniformly mixing, preparing granules, drying, adding the volatile oil, and uniformly mixing to obtain the traditional Chinese medicine.
Example 2 preparation of a Jingfang mixture
Prescription:
97g of schizonepeta, 97g of divaricate saposhnikovia root, 97g of notopterygium root, 97g of radix angelicae pubescentis, 97g of radix bupleuri, 97g of radix peucedani, 97g of ligusticum wallichii, 97g of fructus aurantii, 97g of poria cocos, 97g of platycodon grandiflorum and 32.4g of liquorice;
the preparation method comprises the following steps:
extracting volatile oil from herba Schizonepetae, radix Saposhnikoviae, Notopterygii rhizoma, radix Angelicae Pubescentis, radix Peucedani, rhizoma Ligustici Chuanxiong, and fructus Aurantii respectively, and preparing the water solution of distilled rhizoma Ligustici Chuanxiong and fructus Aurantii into 25% ethanol solution; mixing the residue of rhizoma Ligustici Chuanxiong and fructus Aurantii with Poria, percolating with the above 25% ethanol solution as solvent, collecting percolate, and recovering ethanol under reduced pressure; decocting the distillation residues of herba Schizonepetae, radix Saposhnikoviae, Notopterygii rhizoma, radix Angelicae Pubescentis, and radix Peucedani, bupleuri radix, radix Platycodi, and Glycyrrhrizae radix with water twice for 1.5 hr each time, mixing decoctions, filtering, and concentrating the filtrate to 1300 ml; mixing the percolate and filtrate, standing, filtering, concentrating to 1000ml, adding sodium benzoate 3g and above volatile oil, stirring, and adding water to 1000 ml.
Second, pharmacological experiment
In order to verify the efficacy of the Jingfang preparation in improving or treating the stomach cold syndrome and related diseases thereof, the inventor carries out related pharmacodynamic experimental research. It should be noted that the medicines selected in the pharmacodynamic tests below are the medicines obtained by the representative formula and the preparation method thereof; the inventor also performs pharmacodynamic experiments to the other formulations and the drugs obtained by the preparation method, and the experimental results show that the other formulations and the drugs obtained by the preparation method have the same or similar effects, but the formulations and the drugs are not exhaustive due to space limitations.
In addition, the pharmacodynamic experiments described below only take part of animal models as examples to verify the efficacy of the present invention, and the inventor also performs related pharmacodynamic experiments on other stomach cold related diseases mentioned in the present invention, and the experimental results show that the same or similar effects are achieved, and the experiments are not exhaustive.
The inventor explains that the following experimental studies are carried out on the basis of the safety of the drug proved by acute toxicity tests and long-term toxicity tests, and the administration dose in the experimental studies is within a safe dose range.
The effect of the Jingfang preparation on rats with stomach cold
1 Material
1.1 animals:
SD rat, SPF grade, 180-220 g, the license number of experimental animal: SYXK (lu) 20180008, provided by lumnan pharmaceutical group ltd, was acclimatized for one week prior to the experiment.
1.2 drugs, reagents
1.2.1 medicaments
Jingfang mixture sold in market (national medicine quan-type Z20053800, produced by Lunan Thick pharmaceutical Co., Ltd.)
Commercial Jingfang granules (national Standard Z37020357, Shandong New era pharmaceutical Co., Ltd.)
1.2.3 dosage
Jingfang granules: 4.05g/kg
Jingfang mixture: 5.4ml/kg
2. Modeling, grouping and administering drugs
Taking rats, randomly dividing the rats into a blank group, a model group, a Jingfang granule group and a Jingfang mixture group, feeding the rats of the other groups with ice water at 4 ℃ for 3 times per day for 2 days by gavage of 20ml/kg except for the normal feeding of the blank group, then fasting the rats for 24 hours without water prohibition, and feeding the rats with 10ml/kg of 0.3mol/L cold NaOH solution at 4 ℃ for gavage of 3 days to prepare the stomach cold syndrome model.
Respectively in 3 days before and during the molding, the rats of the Jingfang granule group and the Jingfang mixture group are infused with corresponding liquid medicines, and the rats of the blank group and the model group are infused with physiological saline with the same amount.
After intragastric administration of NaOH solution for 1h on day 3, the rats were sacrificed.
3 Observation index
3.1 histopathological examination
After the rats die, the stomach is taken out, paraffin sections are made after conventional treatment, HE staining is carried out, and gastric mucosa tissues are observed under a light microscope.
3.2 inflammatory factor detection
Collecting blood from femoral artery of rat, separating serum, and detecting contents of interleukin-8 (IL-8), interleukin-2 (IL-2) and interferon-alpha (INF-alpha) in serum.
3.3 statistical treatment
Statistical analysis is carried out on the obtained data by adopting SPSS22.0 software, and the data is measured
The results are shown in the following table, wherein the comparison among the groups is carried out by adopting one-factor analysis of variance, and the analysis between the two groups is carried out by adopting an independent sample T test mode. With P<A difference of 0.05 is statistically significant.
4. Results and conclusions
4.1 rat gastric tissue injury
The gastric mucosa of the rats in the blank group is light red, the surface is smooth and elastic, and the wrinkled wall of the mucosa is complete; the model group rats are congested in gastric mucosa, erosion points and bleeding points appear on the surface, and the wrinkle wall of the gastric mucosa is damaged; the gastric mucosa of the rats in the Jingfang granule group and the Jingfang mixture group is light red, has no hyperemia phenomenon and a small amount of bleeding points, but can be ignored, and the wrinkled wall on the surface of the gastric mucosa has no damage.
The pathological section results of the cases show that the epithelial cells of the gastric mucosa of the rats in the blank group are regularly arranged, the shape of the gastric fundus gland is regular, the structure is clear, and the layers are distinct; the gastric mucosa of the rat in the model group is ulcerated, inflammatory cell infiltrates and glands are damaged; the Jingfang granule group and Jingfang mixture group are used for repairing gastric mucosal ulcer of rats, inflammatory cells are infiltrated in a small amount, and compared with a model group, the gastric mucosal injury condition is obviously improved
The results show that the Jingfang granules and the Jingfang mixture can protect the gastric mucosa of rats and improve the gastric mucosa injury caused by the cold of the stomach.
4.2 inflammatory factors
The content of IL-8, IL-2 and INF-alpha in the serum of the large group of the model group is higher than that of the blank group (P is less than 0.01); the IL-8, IL-2 and INF-alpha in the serum of the rat treated by the Jingfang granules and the Jingfang mixture are obviously reduced (P is less than 0.01).
Table 1 comparison of inflammatory factors in rats of each group (
n＝10)
| Group of | IL-8(ng/mL) | IL-2(ng/mL) | INF-α(ng/mL) |
| Blank group | 0.31±0.06 | 2.67±0.16 | 0.71±0.06 |
| Model set | 0.69±0.04* | 4.32±0.13* | 1.43±0.12* |
| Jingfang granule group | 0.42±0.06* # | 2.96±0.24* # | 0.83±0.08* # |
| Jingfang mixture composition | 0.039±0.05* # | 3.01±0.17* # | 0.81±0.07* # |
Note: in contrast to the blank group, @ P＜0.05，*P＜0.01；
in contrast to the model set, △ P＜0.05， # P＜0.01。
secondly, the effect of the Jingfang preparation on the stomach cold type functional dyspepsia mice
1 Material
1.1 animals:
kunming mouse, SPF level, 18-22 g, and the license number of experimental animal: SYXK (lu) 20180008, provided by lumnan pharmaceutical group ltd, was acclimatized for one week prior to the experiment.
1.2 drugs, reagents
1.2.1 medicaments
Jingfang mixture sold in market (national medicine quan-type Z20053800, produced by Lunan Thick pharmaceutical Co., Ltd.)
Commercial Jingfang granules (national Standard Z37020357, Shandong New era pharmaceutical Co., Ltd.)
1.2.3 dosage
Jingfang granules: 5.85g/kg
Jingfang mixture: 7.8ml/kg
2. Modeling, grouping and administering drugs
Taking 40 mice, randomly dividing into a blank group, a model group, a Jingfang granule group and a Jingfang mixture group, wherein 10 mice in each group are molded for 6 days except for the normal feeding of the blank group, the molding lasts for 1-4 days, the mice freely eat, and are subjected to intragastric administration according to the volume of 20ml/kg for 1 time with ice water at 4 ℃ and 3 times per day; on the 5 th day of molding, the mice are fasted without water supply, and are subjected to gastric lavage with ice water at 4 ℃ for 1 day; on the 6 th day of molding, 0.3mol/L of 4 ℃ cold NaOH solution 0.1ml is administered by intragastric administration.
After modeling, the mice of the Jingfang granule group and the Jingfang mixture group are subjected to intragastric administration and are given corresponding liquid medicines, and the mice of the blank group and the model group are subjected to intragastric administration and are given the same amount of normal saline for 15 days continuously.
3 Observation index
3.1 weight-based growth
The mouse body mass (W) was weighed on the first day of molding 1 ) The body mass of the mice (W) was measured on the last day of administration 21 )。
Mass growth of mouse 21 -W 1
3.2 rate of intestinal transit
After the mice were administered last time, the mice were fasted for 18h, each group of mice was fed with 0.6ml of semisolid paste containing activated carbon powder, and after 30min, the mice were sacrificed, abdomened, and pylorus and small intestine ends were ligated. The small intestine was removed, the total length of the small intestine was recorded, and the end length from the pylorus to the end where the black paste advanced in the intestine was taken as the advanced length, and the small intestine advancement rate was calculated.
3.3 content of gastrodin and motilin
After the mice die, the stomach tissues are taken out, tissue homogenate is prepared, and the enzyme linked immunoassay method is operated according to the kit instruction, so that the gastrotaxin and motilin levels in the stomach tissues are measured.
3.4 statistical treatment
Statistical analysis of the data obtained with SPSS22.0 softwareFor measuring data
The results are shown in the following table, wherein the comparison among the groups is carried out by adopting one-factor analysis of variance, and the analysis between the two groups is carried out by adopting an independent sample T test mode. With P<A difference of 0.05 is statistically significant.
4. Results and conclusions
4.1 general conditions in mice
The mobility of the model group mice is poorer than that of other groups, the hair color is dull, and loose stools are serious; compared with the blank group, the mice in the Jingfang granule group and the Jingfang mixture group have slightly thinner excrement, but the activity of the mice is almost the same as that of the blank group.
4.2 increase in body Mass in mice
Compared with the blank group, the increase of the body mass of the mice in the model group is obviously reduced; the physical quality of the mice in the Jingfang granule group and the Jingfang mixture group is increased almost the same as that of the mice in the blank group.
TABLE 2 comparison of the increase in body Mass of mice in each group (
n＝10)
| Group of | Increase in body Mass (g) |
| Blank group | 13.21±0.36 |
| Model set | 8.21±0.24* |
| Jingfang granule group | 11.35±0.27 @# |
| Jingfang mixture composition | 11.14±0.48 @# |
Note: in contrast to the blank group, @ P＜0.05，*P＜0.01；
in contrast to the model set, △ P＜0.05， # P＜0.01。
4.3 mouse intestinal motility
Compared with the blank group, the intestinal propulsion rate of the model group mice is obviously reduced (P is less than 0.01).
Compared with the model group, the small intestine propulsion rate of the mice in the Jingfang granule group and the Jingfang mixture group is obviously improved (P is less than 0.01).
TABLE 3 comparison of the rate of intestinal propulsion in the groups of mice: (
n＝10)
| Group of | Small intestine propulsion rate (%) |
| Blank group | 33.16±2.47 |
| Model set | 23.15±1.41* |
| Jingfang granule group | 29.34±1.95 @# |
| Jingfang mixture composition | 30.25±2.34 @# |
Note: in contrast to the blank group, @ P＜0.05，*P＜0.01；
in contrast to the model set, △ P＜0.05， # P＜0.01。
4.4 changes in gastrotaxin and motilin in stomach tissue
Compared with the blank group, the level of the gastrodin of the mice in the model group is obviously reduced, and the level of the motilin is obviously increased (P is less than 0.01).
Compared with the model group, the Jingfang granule group and the Jingfang mixture group have obviously increased level of the gastrotaxin and obviously reduced level of the motilin in mice.
TABLE 4 comparison of the gastrotaxin and motilin content in the groups of mice: (
n＝10)
Note: in contrast to the blank group, @ P＜0.05，*P＜0.01；
in contrast to the model set, △ P＜0.05， # P＜0.01。
Claims (8)
1. application of Jingfang preparation in preparing medicine for improving and/or treating stomach cold syndrome is provided.
2. Use of JING FANG ZHI JI in preparing medicine for relieving stomach ache, dyspepsia or emesis caused by stomach cold is provided.
3. Use of JING FANG ZHI JI in preparing medicine for treating or adjunctively treating stomach diseases due to stomach cold is provided.
4. The use of claim 3, wherein the gastric disease includes, but is not limited to, gastric ulcer, duodenal ulcer, chronic gastritis, gastroptosis, gastroneurosis, prolapse of gastric mucosa.
5. The use according to any one of claims 1 to 4, wherein the Jingfang preparation is prepared from the following raw materials:
75 parts by weight of schizonepeta, 75 parts by weight of divaricate saposhnikovia root and 75 parts by weight of notopterygium root
75 parts of pubescent angelica root, 75 parts of bupleurum root, 75 parts of whiteflower hogfennel root
75 parts of ligusticum wallichii, 75 parts of fructus aurantii and 75 parts of poria cocos
75 parts of platycodon grandiflorum and 25 parts of liquorice.
6. The use according to any one of claims 1 to 4, wherein the Jingfang preparation is a clinically acceptable oral preparation.
7. The use of claim 6, wherein the clinically acceptable oral formulation includes, but is not limited to, granules, oral liquids, mixtures, syrups, tablets, capsules.
8. The use according to claim 7, wherein the oral formulation is a granulate and/or a mixture.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110296997 | 2021-03-19 | ||
| CN202110296997X | 2021-03-19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN115105546A true CN115105546A (en) | 2022-09-27 |
Family
ID=83324801
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210248173.XA Pending CN115105546A (en) | 2021-03-19 | 2022-03-14 | Application of Jingfang preparation in improving or treating stomach cold syndrome |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN115105546A (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112353863A (en) * | 2020-09-23 | 2021-02-12 | 鲁南制药集团股份有限公司 | Application of Jingfang preparation in preparation of medicine for treating gastric ulcer and preparation method of Jingfang preparation |
| CN112386635A (en) * | 2020-09-23 | 2021-02-23 | 鲁南制药集团股份有限公司 | Application of Jingfang preparation in preparing medicine for treating new coronary sequelae and preparation method thereof |
-
2022
- 2022-03-14 CN CN202210248173.XA patent/CN115105546A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112353863A (en) * | 2020-09-23 | 2021-02-12 | 鲁南制药集团股份有限公司 | Application of Jingfang preparation in preparation of medicine for treating gastric ulcer and preparation method of Jingfang preparation |
| CN112386635A (en) * | 2020-09-23 | 2021-02-23 | 鲁南制药集团股份有限公司 | Application of Jingfang preparation in preparing medicine for treating new coronary sequelae and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN109674958B (en) | Traditional Chinese medicine composition with effect of reducing uric acid and preparation method and application thereof | |
| CN103520293B (en) | Improve and treat the Chinese medicine for oral administration of constipation | |
| CN105582124B (en) | Chinese medicinal composition for treating constipation, and its preparation method | |
| CN114073731A (en) | A Chinese medicinal composition for treating abdominal pain and diarrhea | |
| CN101829291B (en) | Traditional Chinese medicine preparation for treating rheumatism and preparation method thereof | |
| CN106266949A (en) | A kind of compound Chinese medicinal preparation and its preparation method and application | |
| CN103463382B (en) | Traditional Chinese medicine for treating constipation, and preparation method and application thereof | |
| CN103394002B (en) | Medicinal composition for treating cutaneous pruritus as well as preparation method and application thereof | |
| CN115105546A (en) | Application of Jingfang preparation in improving or treating stomach cold syndrome | |
| CN112274619B (en) | Composition for relieving dysmenorrhea and application of composition in preparation of medicines, health-care products or foods | |
| CN104435567A (en) | Traditional Chinese medicinal composition containing gynostemma pentaphyllum for treating gout | |
| CN114470114A (en) | Application of Mailuoshutong preparation in preparation of medicine for treating constipation | |
| CN1292789C (en) | Infant's Runtu granulars and preparation method | |
| CN104095940B (en) | A kind of Chinese medicine composition for the treatment of gout | |
| CN105749127A (en) | Pharmaceutic preparation for treating stomach cancer and application thereof | |
| CN1128632C (en) | Traditional Chinese medicine compound preparation for treating chronic hepatitis B and preparation process thereof | |
| CN114272295A (en) | Traditional Chinese medicine composition for treating diabetic acromelic gangrene | |
| CN105012552A (en) | Traditional Chinese medicine for treating wind-prevailing migratory arthralgia type rheumatic arthritis and preparation method | |
| CN104337898B (en) | A kind of Chinese medicine composition of the treatment gout containing Semen Pruni | |
| CN103800449B (en) | A kind of Chinese medicine composition for the treatment of Yin Xu Nei Re Zheng type 2 diabetes mellitus | |
| CN113171439B (en) | Oral medicine for treating defensive exterior insecurity type chronic urticaria | |
| CN110215474B (en) | Traditional Chinese medicine composition for promoting blood circulation to remove blood stasis and application thereof | |
| CN114146121A (en) | Application of traditional Chinese medicine composition in preparation of medicine for treating dyspepsia | |
| CN1446554A (en) | Medicine for treating acute cholecystitis and chronic cholecystitis and its preparing method | |
| CN115192664A (en) | Traditional Chinese medicine composition and medical application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |